Cardiff Oncology to Participate in the UBS Global Biopharma Conference
Globe Newswire•03/11/2026•07:00 ET
0
Key Highlights
- ➤Cardiff Oncology management to present at UBS Global Biopharma Conference November 16-17, 2026
- ➤Mani Mohindru scheduled for a fireside chat November 16 at 2:40 PM GMT
- ➤Cardiff’s lead asset onvansertib is being evaluated in a Phase 2 first-line RAS-mutated mCRC trial
- ➤Onvansertib is also under investigation in other PLK1-driven cancers
Expert Statements
Mani Mohindru, President and CEO of Cardiff Oncology
“Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers”
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026.
Format: Fireside Chat Presenter: Mani Mohindru, PhD (President and CEO) Date: November 16, 2026 Time: 2:40 PM GMT
Get started
Create a free account to read the full story.